Osteoporosis drug, denosumab, has a good safety profile – new study

Denosumab, a drug used to treat osteoporosis, has performed well in a new study published in the Journal of Bone and Mineral Research.

Denosumab is given as an injection under the skin twice a year. It limits the activity of cells that break down old bone material by blocking a particular protein.

Now a new study has found that negative side effects revealed in a trial in women aged 60 to 90 years old treated for three years, showed no tendency to increase after a further three years of treatment.

And women who crossed over from three years of placebo to three years of denosumab experienced no increase in adverse effects compared with women treated for the initial three years.

“All of this is consistent with an excellent safety and tolerability profile for denosumab treatment for osteoporosis,” explains Dr Nelson Watts, lead author.

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.